Transcenta Debuts On Hong Kong Stock Exchange Transcenta holding limited 創勝集團醫藥有限公司 (registered by way of continuation in the cayman islands with limited liability) global offering number of offer shares under the global offering: 40,330,000 shares (subject to the over allotment option) number of hong kong public offer shares: 4,033,000 shares (subject to reallocation). 2552.hk hua medicine (shanghai) ltd. 1.150. 0.86%. find the latest transcenta holding limited (6628.hk) stock quote, history, news and other vital information to help you with your stock trading.
Transcenta Debuts On Hong Kong Stock Exchange Transcenta holding ltd is a china based investment holding company engaged in the discovery, research, development, manufacturing and business development of biopharmaceuticals in the clinical stage. the company's products in clude msb2311, tst001, tst005, tst002, tst004, tst003, tst008, msb0254 and tst006. the company also provides contract. Transcenta is a clinical stage biopharmaceutical company that fully integrates antibody based biotherapeutics discovery, research, development and manufacturing. on september 29, 2021, transcenta was listed on the main board of the stock exchange of hong kong limited with the stock code: 06628. About transcenta holding limited transcenta (hkex: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody based biotherapeutics discovery, research. Transcenta holding limited 創勝集團醫藥有限公司 (registered by way of continuation in the cayman islands with limited liability) (stock code: 6628) list of directors and their roles and functions the members of the board of directors (the “board ”) of transcenta holding limited (the “company”) are set out below. executive director.
Comments are closed.